The University of Southampton
University of Southampton Institutional Repository

Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature

Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature
Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature

Introduction: Prostate cancer is the most common cancer amongst men in the UK. Treatments for malignant ureteric obstruction consist of percutaneous nephrostomy, ureteric stent insertion, or occasionally other forms of urinary diversion. Our aim was to look at the outcomes of percutaneous nephrostomy (PCN) in patients with advanced prostate cancer and to look at the impact on patient's general health, quality of life, life expectancy and complications after PCN insertion.

Material and methods: A systematic review of the literature was done for all prospective English language articles on PCN in patients with prostate cancer using PubMed, MEDLINE, EMBASE, Scopus, CINAHL, Cochrane library, Clinicaltrials.gov, Google Scholar and individual urological journals from inception to August 2017. While studies involving prostate cancer patients were included, studies on all other mixed pelvic malignancies were excluded.

Results: Seven articles met the inclusion criteria. There were 184 patients, with a mean age of 70 years (range: 51-94 years). PCN was performed for ureteric obstruction due to advanced prostate cancer, patients underwent unilateral (n = 66) or bilateral PCN (n = 118) with conversion to an antegrade stent in 25 patients. Their post-PCN survival varied between 4-31 months and this was longer if they were hormone naïve or showed a good recovery in their renal function. Although the complication rates were low (1-3%), patients spend a high proportion of their lives in the hospital.

Conclusions: PCNs should only be pursued after thoughtful counselling regarding further treatment options and prognosis as these patients with advanced malignancies seem to have reduced survival duration and spend a significant amount of time in hospital.

2080-4806
404-409
New, Francesca
a0d0c2ab-a96b-42b2-9512-26dc6ca197d2
Deverill, Sally
9cdca666-599c-4eaf-aabb-f055adf0d03f
Somani, Bhaskar K.
ab5fd1ce-02df-4b88-b25e-8ece396335d9
New, Francesca
a0d0c2ab-a96b-42b2-9512-26dc6ca197d2
Deverill, Sally
9cdca666-599c-4eaf-aabb-f055adf0d03f
Somani, Bhaskar K.
ab5fd1ce-02df-4b88-b25e-8ece396335d9

New, Francesca, Deverill, Sally and Somani, Bhaskar K. (2018) Role of percutaneous nephrostomy in end of life prostate cancer patients: a systematic review of the literature. Central European Journal of Urology, 71 (4), 404-409. (doi:10.5173/ceju.2018.1780).

Record type: Review

Abstract

Introduction: Prostate cancer is the most common cancer amongst men in the UK. Treatments for malignant ureteric obstruction consist of percutaneous nephrostomy, ureteric stent insertion, or occasionally other forms of urinary diversion. Our aim was to look at the outcomes of percutaneous nephrostomy (PCN) in patients with advanced prostate cancer and to look at the impact on patient's general health, quality of life, life expectancy and complications after PCN insertion.

Material and methods: A systematic review of the literature was done for all prospective English language articles on PCN in patients with prostate cancer using PubMed, MEDLINE, EMBASE, Scopus, CINAHL, Cochrane library, Clinicaltrials.gov, Google Scholar and individual urological journals from inception to August 2017. While studies involving prostate cancer patients were included, studies on all other mixed pelvic malignancies were excluded.

Results: Seven articles met the inclusion criteria. There were 184 patients, with a mean age of 70 years (range: 51-94 years). PCN was performed for ureteric obstruction due to advanced prostate cancer, patients underwent unilateral (n = 66) or bilateral PCN (n = 118) with conversion to an antegrade stent in 25 patients. Their post-PCN survival varied between 4-31 months and this was longer if they were hormone naïve or showed a good recovery in their renal function. Although the complication rates were low (1-3%), patients spend a high proportion of their lives in the hospital.

Conclusions: PCNs should only be pursued after thoughtful counselling regarding further treatment options and prognosis as these patients with advanced malignancies seem to have reduced survival duration and spend a significant amount of time in hospital.

This record has no associated files available for download.

More information

Accepted/In Press date: 17 November 2018
e-pub ahead of print date: 29 November 2018
Published date: 2018

Identifiers

Local EPrints ID: 433336
URI: http://eprints.soton.ac.uk/id/eprint/433336
ISSN: 2080-4806
PURE UUID: 82fece88-647e-4eda-98a0-d274d7f134e4

Catalogue record

Date deposited: 14 Aug 2019 16:30
Last modified: 16 Mar 2024 03:24

Export record

Altmetrics

Contributors

Author: Francesca New
Author: Sally Deverill

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×